Acrivon Therapeutics (ACRV) Expected to Release Quarterly Earnings on Thursday

Acrivon Therapeutics (NASDAQ:ACRV) is projected to announce its Q3 2026 resultson Thursday, November 12th. Analysts expect Acrivon Therapeutics to post earnings of ($0.45) per share and revenue of $0.50 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.07. On average, analysts expect Acrivon Therapeutics to post ($1.76) EPS for the current fiscal year and ($1.40) EPS for the next fiscal year.

Acrivon Therapeutics Stock Performance

Acrivon Therapeutics stock opened at $1.74 on Thursday. The stock has a market capitalization of $74.56 million, a price-to-earnings ratio of -0.93 and a beta of 1.96. Acrivon Therapeutics has a 52-week low of $1.27 and a 52-week high of $3.56. The stock’s 50 day moving average price is $1.91 and its two-hundred day moving average price is $1.76.

Insider Activity at Acrivon Therapeutics

In related news, CEO Peter Blume-Jensen sold 14,036 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $2.21, for a total value of $31,019.56. Following the completion of the sale, the chief executive officer directly owned 2,230,052 shares of the company’s stock, valued at $4,928,414.92. The trade was a 0.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 17,345 shares of company stock valued at $37,578. Company insiders own 10.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Weiss Ratings upgraded shares of Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 9th. Wall Street Zen raised shares of Acrivon Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, October 5th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines for patients with difficult-to-treat cancers. The company uses its proprietary OncoSignature platform to identify tumor characteristics that may predict a patient’s response to a particular therapy, with the goal of matching treatments to the patients most likely to benefit.

Acrivon’s lead investigational product is ACR-368, an oral small-molecule therapy designed to target cell-cycle checkpoint mechanisms that cancer cells rely on for survival.